Business Context and Reporting Period
Company: Aquestive Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 12, 2022
Event: Entry into a Material Definitive Agreement (Equity Line of Credit) with Lincoln Park Capital Fund, LLC.
Key Financial Metrics and Transaction Terms
- Total Facility Size: Up to $40,000,000 in common stock sales over a 36-month term.
- Initial Commitment Shares: 225,310 shares issued immediately on April 12, 2022, as consideration for the commitment.
- Additional Commitment Shares: Up to 225,310 shares may be issued in the future on a pro rata basis.
- Exchange Cap: Total issuance (including commitment shares) is capped at 8,323,114 shares (19.99% of outstanding shares) unless shareholder approval is obtained or the average issuance price meets or exceeds $2.16 per share.
- Beneficial Ownership Limit: Lincoln Park cannot be directed to purchase shares if it would result in beneficial ownership exceeding 9.99% of outstanding common stock.
- Use of Proceeds: Working capital and general corporate purposes.
Material Changes and Pricing Mechanics
The filing details a new "at-the-market" equity facility with specific pricing tiers based on market conditions:
- Regular Purchases:
- Standard: Up to 100,000 shares per day.
- Increased to 200,000 shares if closing price is $\ge$ $3.00.
- Increased to 300,000 shares if closing price is $\ge$ $4.00.
- Price: Lesser of the lowest sale price on the purchase date or the average of the three lowest closing prices in the prior 10 business days.
- Accelerated Purchases:
- Available only after a maximum Regular Purchase is executed.
- Volume: Up to 3x the Regular Purchase amount or 30% of trading volume (whichever is lower).
- Price: 97% of the lower of the volume-weighted average price (during the measurement period) or the closing sale price.
Guidance, Risks, and Management Commentary
- Termination Rights: The Company may terminate the agreement at any time at its sole discretion without cost or penalty; however, Commitment Shares are non-refundable.
- Covenants: No financial or business covenants, restrictions on future financings (except similar equity lines), rights of first refusal, or penalties.
- Short Selling: Lincoln Park has covenanted not to engage in direct or indirect short selling or hedging of the Company's common stock.
- Regulatory Status: The Company is an emerging growth company. The transaction is registered under an effective Form S-3 shelf registration statement.
Investor Verification Checklist
- Verify the current number of outstanding shares to calculate the precise percentage dilution of the 225,310 Initial Commitment Shares.
- Monitor the stock price relative to the $2.16 threshold to determine if the 19.99% Exchange Cap can be bypassed without shareholder approval.
- Review the prospectus supplement filed on April 13, 2022, for full legal terms and risk factors.
- Track future "Purchase Notices" to assess the Company's actual capital raising activity and dilution impact over the 36-month term.